R

Roche

Global pharmaceuticals and diagnostics company

Regulatory AI & Automation Specialist

Full-TimeUpdated
No salary listed
Mid, Senior
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Software EngineeringAI Application Engineering

About the job

Requirements
  • Bachelor’s or Master’s degree in Computer Science, Data Science, Information Technology, Statistics, or a related quantitative field, with 4–6 years of hands-on experience building and deploying software, automation, or AI/ML solutions.
  • Direct experience in pharmaceutical R&D regulatory affairs or clinical development.
  • Experience with prompt evaluation frameworks or multi-agent orchestration.
  • Advanced proficiency in Python and SQL for data extraction, manipulation, pipeline creation, and writing modular, production-ready code.
  • Practical experience with Natural Language Processing, Optical Character Recognition such as Tesseract, AWS Textract, or Azure AI Document Intelligence, and parsing unstructured PDFs, XML, JSON, and Word documents.
  • Hands-on experience developing application logic using modern large language model frameworks such as LangChain, LlamaIndex, OpenAI or AWS Bedrock APIs, and building Retrieval-Augmented Generation pipelines for document querying.
  • Experience with REST APIs, Git version control, unit testing, and basic CI/CD practices.
  • Experience automating workflows using Python orchestration, low-code automation tools such as Power Automate or UiPath, or enterprise schedulers.
  • Basic exposure to AWS or Azure cloud platforms and Docker containerization for deploying scripts and API services.
Responsibilities
  • Collaborate with regulatory stakeholders to evaluate incoming AI and automation requests, assess technical feasibility, and help prioritize high-value use cases for regulatory document workflows.
  • Build and deploy scalable AI, machine learning, and automation solutions integrating robotic process automation, low-code/no-code platforms, Python, natural language processing, and cloud-native services such as AWS to optimize global regulatory workflows and document management.
  • Perform operational process mining and opportunity mapping with subject-matter experts from the PDR Innovation and Sustainment chapter and global regulatory teams to identify high-impact AI and automation opportunities.
  • Support the IT team by providing business direction for ongoing technical and preventive maintenance, performance monitoring, and troubleshooting of deployed automation scripts, machine learning models, and AI assets in production.
  • Maintain technical artifacts, including solution architecture, source code repositories, and testing frameworks, and conduct hands-on internal training to drive adoption across global regulatory functions.
  • Drive cross-functional Agile and DevOps execution with chapter leads, regulatory teams, IT, and RSS peers through sprint planning, rapid proof-of-concept prototyping, iterative testing, and continuous feedback loops.
  • Monitor operational performance metrics and deliver project updates, technical insights, and continuous-improvement recommendations to functional leadership and regulatory stakeholders.
  • Partner with global regulatory teams to demonstrate practical applications of AI, natural language processing, and automation, translating technical features into business benefits such as compliance-risk reduction, improved document-processing throughput, and operational efficiency.
Desired Qualifications
  • Ability to design complex, multi-step prompts, validate outputs against business logic, and refine solutions iteratively.
  • Foundational knowledge of ICH guidelines, FDA/EMA submission processes, regulatory document formats such as eCTD and GxP guidelines, CT documentation, and emerging AI/ML regulatory guidance.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 28th, 2026
Roche launches BAP1 test to distinguish mesothelioma from other cancers

Roche has launched the VENTANA BAP1 (SP527) test worldwide to help diagnose mesothelioma, a rare and deadly cancer. The automated immunohistochemistry assay helps pathologists tell mesothelioma apart from other cancers, including non-small cell lung cancer, and from benign tissue growth. The test is registered as a Class I IVD with the US Food and Drug Administration and has IVDR approval as a Class C device. Roche announced the launch in Basel on October 28, 2026. Most patients are diagnosed late, with median overall survival of just 12 to 18 months. BAP1 works alongside the recently launched MTAP and Claudin-4 tests, which help preserve limited tissue samples for molecular sequencing. "Timely differential diagnosis of mesothelioma is critical to help deliver the best outcome for patients," said Matt Sause, chief executive officer of Roche Diagnostics.

Yahoo Finance
Oct 27th, 2026
Zymeworks signs Roche deal worth up to $718M in milestones, shows 65% response in ovarian cancer

Zymeworks has agreed a collaboration with Roche on ZW209, a T-cell engager that targets DLL3-positive tumours, including small cell lung cancer. The deal is subject to Hart-Scott-Rodino Act clearance. Zymeworks would receive $55 million upfront and $40 million when a Phase 1b study begins. It could also earn up to $718 million in milestones, plus tiered royalties from high single digits to mid-teens. Roche would fund research and development, and take over later development and commercialisation. Zymeworks will run the first global trial. Zymeworks also reported updated data for ZW191 in platinum-resistant ovarian cancer. In high-grade serous disease, confirmed response rates were 65% at 6.4 mg/kg and 55% at 9.6 mg/kg. The company is seeking partners to fund further development.

Yahoo Finance
Oct 27th, 2026
Roche wins CE Mark for compact cobas smart e immunoanalyser with 100+ planned assays

Roche has received the CE Mark for its cobas smart e immunoanalyser, a compact testing platform for smaller hospitals and laboratories. The company announced the approval in Basel on October 27, 2026. The device fits in a footprint of under one square metre and has a planned menu of over 100 assays. Reaction times are 18 minutes or less for more than 90% of Roche immunoassays, which can help local facilities cut turnaround times. It uses the same reagents and Elecsys technology as Roche's high-throughput systems, so results stay consistent across sites. Roche says it needs one minute of daily operator input and cuts hands-on maintenance by up to two-thirds compared with earlier platforms. It joins the cobas e 402 and cobas e 801 units, completing a range for clinics through to large hospital laboratories.

Yahoo Finance
Oct 26th, 2026
Zymeworks licenses ZW209 to Roche in deal worth up to $813M, with $55M upfront

Zymeworks has granted Roche exclusive worldwide rights to develop and commercialise ZW209, a DLL3-targeting trispecific T-cell engager. The deal brings $55.0 million upfront, up to $758.0 million in further milestones, and tiered royalties. Roche will take on most later development and commercialisation work. That fits Zymeworks' partnership-heavy, capital-light model, though future cash from ZW209 now depends largely on Roche meeting its own targets. The company also reported Phase 1 data for ZW191, an ovarian cancer antibody-drug conjugate. It showed activity across folate receptor alpha expression levels and a more favourable tolerability profile at 6.4mg/kg.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.